Echo Therapeutics Announces First Quarter 2013 Financial Results PR Newswire PHILADELPHIA, May 10, 2013 PHILADELPHIA, May 10, 2013 /PRNewswire/ --Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony^® CGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, today announced financial results for the quarter ended March 31, 2013. Echo's Quarterly Report on Form 10-Q, as filed with the SEC, will be available by visiting the Investors section of Echo's website at www.echotx.com. (Logo: http://photos.prnewswire.com/prnh/20120801/NE50071LOGO) Recent Corporate Highlights oIn March, Echo was granted International Standards Organization (ISO) 13485:2003 certification of its quality system. ISO 13485:2003 is an internationally recognized standard that prescribes consistent processes for the development, design and manufacturing of medical devices and represents an important step toward attaining European CE Mark approval. oEcho completed a public offering of approximately $10.6 million, after expenses, in February. Echo also voluntarily prepaid the $3 million outstanding balance of its $20 million credit facility with Platinum-Montaur Life Sciences, LLC. oEcho participated in various medical and investor conferences and symposia. In January, Echo presented data during a poster session at the Society of Critical Care Medicine's (SCCM) Annual Meeting and, in February, Echo exhibited its Symphony CGM technology at the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD). In January, management presented to prospective corporate partners and investors at the Noble Financial Markets' Ninth Annual Equity Conference and at the Biotech Showcase 2013 Conference. oEcho appointed Robert F. Doman to its Board of Directors in March. Mr. Doman brings over 30 years of executive level, international and domestic management, business development, sales and marketing, product development and strategic planning experience with specific concentrations in medical devices and pharmaceuticals. oEcho announced that the U.S. Patent and Trademark Office (USPTO) issued U.S. Patent 8,386,027, "Skin Permeation Device for Analyte Sensing or Transdermal Drug Delivery," for the skin permeation component of the Symphony CGM System. Echo currently holds 8 U.S. patents and at least 70 foreign patents, and has at least 25 patent applications pending in the U.S. and foreign countries. "Design freeze of our Symphony CGM System and the ISO 13485 certification of our quality management system in the first quarter validated the progress we made in 2012. We are on track to conduct our multi-center CE Mark pivotal trial and to submit our CE Technical File in the near term," commented Patrick T. Mooney, M.D., Chairman and Chief Executive Officer of Echo Therapeutics. "With several important milestones still ahead, we look forward to increased shareholder value and commercializing Symphony in Europe later this year." First Quarter 2013 Financial Results Echo's net loss for the first quarter of 2013 was $7.0 million, or ($0.13) per share, compared to $3.0 million, or ($0.08) per share, for the first quarter of 2012. Operating loss for the first quarter of 2013 was $5.5 million compared to $3.2 million for the first quarter of 2012. Research and development expenses were $3.2 million for the first quarter of 2013 compared to $1.4 million in the prior year. Research and development expenses increased primarily as a result of greater engineering and design expenses incurred with outside contractors and personnel. General and administration expenses were $2.3 million for the first quarter of 2013 versus $1.9 million in the prior year. The Company reported a cash balance of approximately $5.2 million as of March 31, 2013. Conference Call Management will host a conference call today starting at 9:00 AM EDT. To listen in and/or participate in the call, please dial (877) 317-6789 and reference the conference number 10028680. The archived audiocast will be available for fourteen days following the call by visiting the Events section of Echo's website at www.echotx.com. About Echo Therapeutics Echo Therapeutics is developing the Symphony CGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system. Our target is patients who could benefit from glucose monitoring in the hospital setting, including critical care. Significant opportunity also exists for patients with diabetes to use Symphony in the outpatient setting. Echo is also developing its needle-free skin preparation component of Symphony, the Prelude^® SkinPrep System, as a platform technology to enhance drug delivery of topical pharmaceuticals. Cautionary Statement Regarding Forward Looking Statements The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's ongoing studies, including the safety and efficacy of Echo's Symphony CGM System, the failure of future development and preliminary marketing efforts related to Echo's Symphony CGM System, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's and its partners' ability to develop, market and sell the Symphony CGM System, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony CGM System. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the year ended December 31, 2012, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements. For More Information: Christine H. Olimpio Director, Investor Relations and Corporate Communications (215) 717-4104 Connect With Us: - Visit our website at www.echotx.com - Follow us on Twitter at www.twitter.com/echotx - Join us on Facebook at www.facebook.com/echotx Echo Therapeutics, Inc Condensed Consolidated Balance Sheets March 31, December 31, 2013 2012 ASSETS Current Assets: Cash and cash equivalents $ 5,170,251 $ 3,747,210 Cash restricted pursuant to letters 657,463 407,463 of credit Deferred financing costs, current 968,004 968,004 portion Prepaid expenses and other current 231,171 75,626 assets Total current assets 7,026,889 5,198,303 Net property and equipment (including assets under capitalized 1,678,464 1,638,395 leases) Intangible assets, net of 9,625,000 9,625,000 accumulated amortization Deferred financing costs, net of 3,307,327 3,549,328 current portion Restricted cash, deposits and other 10,566 10,566 assets Total assets $ 21,648,246 $ 20,021,592 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable $ 1,499,294 $ 2,319,219 Deferred revenue from licensing 67,671 90,228 arrangements Capital lease obligations, current 2,591 2,527 portion Derivative warrant liability 3,904,155 5,585,141 Accrued expenses and other 1,759,537 1,581,448 liabilities Total current liabilities 7,233,248 9,578,563 Deferred revenue, note payable and capital lease obligation, net of 90,917 212,423 current portion Total liabilities 7,324,165 9,790,986 Commitments Stockholders' Equity: Convertible preferred stock, Series 30,160 30,160 C & D Common stock 602,449 443,737 Additional paid-in capital 114,581,812 103,658,724 Accumulated deficit (100,890,340) (93,902,015) Total stockholders' equity 14,324,081 10,230,606 Total liabilities and stockholders' $ 21,648,246 $ 20,021,592 equity Condensed Consolidated Statements of Operations Three Months Ended March 31, 2013 2012 Licensing revenue $ 22,557 $ 30,927 Total revenues 22,557 30,927 Operating Expenses: Research and development 3,219,723 1,391,645 Selling, general and administrative 2,299,447 1,859,404 Total operating expenses 5,519,170 3,251,049 Loss from operations (5,496,613) (3,220,122) Other Income (Expense): Interest income (expense), net (3,172,698) 2,809 Gain on revaluation of derivative 1,680,986 231,543 warrant liability Other income (expense), net (1,491,712) 234,352 Net loss (6,988,325) (2,985,770) Net loss per common share, basic and $ (0.13) $ diluted (0.08) Basic and diluted weighted average 53,734,767 38,742,976 common shares outstanding SOURCE Echo Therapeutics, Inc. Website: http://www.echotx.com
Echo Therapeutics Announces First Quarter 2013 Financial Results
Press spacebar to pause and continue. Press esc to stop.